• DOI:10.2174/138161212802884681
Corpus ID: 13446596

A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.

@article{Zuardi2012ACR,
  title={A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.},
  author={A. W. Zuardi and J. Crippa and J. Hallak and S. Bhattacharyya and Z. Atakan and R. Martin-Santos and P. McGuire and F. Guimar{\~a}es},
  journal={Current pharmaceutical design},
  year={2012},
  volume={18 32},
  pages={
          5131-40
        }
}

A. W. Zuardi, J. Crippa, +5 authors F. Guimarães

Published 2012

Medicine

Current pharmaceutical design

Δ(9)-tetrahydrocannabinol (Δ(9)-THC) is the main compound of the Cannabis Sativa responsible for most of the effects of the plant. Another major constituent is cannabidiol (CBD), formerly regarded to be devoid of pharmacological activity. However, laboratory rodents and human studies have shown that this cannabinoid is able to prevent psychotic-like symptoms induced by high doses of Δ(9)- THC. Subsequent studies have demonstrated that CBD has antipsychotic effects as observed using animal… CONTINUE READING

View PDF

Save to Library

Create Alert

Cite

Launch Research Feed